Management decisions for patients with chronic myeloid leukemia (CML) have become
remarkably complex due to a variety of highly effective treatment options. Therapy for …

Imatinib mesylate, a targeted inhibitor of BCR-ABL tyrosine kinase, is the standard of care for
chronic myeloid leukemia (CML). A phase 2 trial of imatinib in late chronic-phase (CP) CML …

Background Imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase, produces high
response rates in patients with chronic-phase chronic myeloid leukemia (CML) who have …

We analyzed molecular responses in 55 newly diagnosed chronic-phase chronic myeloid
leukemia (CML) patients enrolled in a phase 3 study (the IRIS trial) comparing imatinib to …

This study examines the prognostic significance of early molecular response using an
expanded dataset in chronic myeloid leukemia patients enrolled in the International …

Imatinib mesylate is very effective in the treatment of chronic myelogenous leukemia (CML)
and 400 mg/day imatinib is considered the standard treatment dose for chronic-phase (CP) …

In the multinational IRIS study comparing imatinib with interferon plus cytarabine (IFN/Ara-C)
in patients with newly diagnosed chronic-phase chronic myelogenous leukemia (CP CML) …

Abstract BACKGROUND. Interferon‐alpha (IFN‐α) confers a survival advantage for the
minority of patients with chronic myeloid leukemia (CML) who achieve a complete …

Abstract Abstract 1126 Poster Board I-148 Background The IRIS study demonstrated
superior safety and efficacy of imatinib (IM) relative to interferon-αa+ cytarabine. Based on …

Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-
in Newly Diagnosed Chronic Myeloid Leuke Page 1 Tolerability-Adapted Imatinib 800 mg/d …